Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2024 Earnings Conference Call November 12, 2024 8:00 AM ET
Company Participants
Stephanie Lee - Investor Relations
Matt Gline - Chief Executive Officer
Ben Zimmer - Chief Executive Officer, Priovant
Conference Call Participants
Louise Chen - Cantor
Brian Cheng - JPMorgan
Joyce Zhou - TD Cowen
Andy Chen - Wolfe Research
Douglas Tsao - H.C. Wainwright
Craig McLean - Goldman Sachs
Operator
Good day and thank you for standing by. Welcome to the Roivant Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Stephanie Lee. Please go ahead.
Stephanie Lee
Good morning, and thanks for joining today's call to review Roivant's financial results for the second quarter ended September 30, 2024. I'm Stephanie Lee with Roivant. Presenting today, we have Matt Gline, CEO of Roivant; and Ben Zimmer, CEO of Priovant.
For those dialing in via conference call, you can find the slides being presented today, as well as a press release announcing these updates on our IR website at www.investor.roivant.com. We'll also be providing the current slide numbers as we present to help you follow along.
I'd like to remind you that we'll be making certain forward-looking statements during today's presentation. We strongly encourage you to review the information that we filed with the SEC for more information regarding these forward-looking statements and related risks and uncertainties.
With that, I'll turn it over to Matt.
Matt Gline
Thank you, Stephanie. Thank you to the operator, and thank you everyone for dialing in this morning. We actually have a relatively full update. So I'm excited to share and there's at least one major new thing we're going to talk about, which is the 52-week data from our NIU study, which I'm pretty excited about.
So starting on slide five, look, I think there's really two major areas of focus for us right now. And the first is clinical trial execution. We have a lot of ongoing trials, all of which are important and are going to generate interesting data coming in the near future here. Obviously, today, we're talking about the 52-week data for brepocitinib in NIU in the Phase 2 study, where also the Phase 3 study is ongoing with the first patients enrolled and with fast-track designations having been granted. We presented this quarter batoclimab in Graves' disease.